The pandemic of Coronavirus disease 2019 (COVID-19) is rapidly progressing, causing significant morbidity and mortality. Various antiviral drugs, anti-inflammatory drugs and immunomodulators have been tried without substantial clinical benefits. The severe and critical cases of COVID-19 disease are characterised by gut microbiome dysbiosis, immune dysregulation, hyper-inflammation and hypercytokinaemia (cytokine storm). Therefore, the strategies which target these pathophysiological processes may be beneficial. Probiotics are one such strategy that exerts beneficial effects by manipulation of the gut microbiota, suppression of opportunistic pathogens in the gut, decreasing translocation of opportunistic organisms, activation of mucosal immunity and modulation of the innate and adaptive immune response. Probiotics are the potential candidates to be tested in moderate and severe cases of COVID-19 due to several beneficial effects, including easy availability, easy to administer, safe and economical to use.
【저자키워드】 Coronavirus disease 2019, Cytokine storm, Probiotics, gut microbiome, Dysbiosis, 【초록키워드】 COVID-19, pandemic, Immunity, antiviral drugs, COVID-19 disease, immunomodulator, pathogen, Microbiome, hyper-inflammation, gut microbiota, morbidity and mortality, Adaptive immune response, moderate, mucosal, Gut, Safe, immune dysregulation, Activation, Organisms, Critical case, modulation, clinical benefits, candidate, Severe case, anti-inflammatory drug, translocation, Effect, Effects, tested, administer, pathophysiological, 【제목키워드】 disease,